[摘要] 目的：观察丹参川芎嗪注射液与阿托伐他汀联用对急性脑梗死（AC

[Abstract] Objective: To observe the homocysteine ​​(Hcy), hypersensitivity C-reactive protein (hs-CRP) and cystatin C of patients with acute cerebral infarction (ACI) combined with Danshen Ligustrazine Injection and Atorvastatin (CysC). Methods: According to the random number table method, 104 ACI patients admitted to our hospital from February 2018 to August 2019 were divided into a treatment group (n = 52) and a reference group (n = 52). The patients in the reference group were given atorvastatin treatment. The treatment group was treated with atorvastatin and Danshen ligustrazine injection. The levels of Hcy, h-CRP and CysC were compared between the two groups before and after treatment. Efficacy and incidence of adverse reactions. Results: After treatment, the above indicators in both groups were significantly lower than before treatment (P <0.05), and the treatment group was significantly lower than the reference group (P <0.05); the clinical effective rate of the treatment group (86.54%) was significantly higher than the reference group ( 69.23%) (P <0.05); the incidence of adverse reactions between the two groups was not significant (P> 0.05). Conclusion: Danshen ligustrazine injection combined with atorvastatin in the treatment of ACI can significantly improve the patient's microcirculation, reduce the levels of Hcy, hs-CRP, CysC, and improve the clinical efficacy.

Objective: To observe the effect of dansanchuan incombination injections with atoflavin to patients with acute cerebral infarction (ACI) homocysteine (Hcy) and hypersensitivity C reactive protein (hs-CRP), cystin C (CysC). Methods: The 104 ACI patients admitted to the hospital from February 2018 to August 2019 were divided into the treatment group (n-52) and the reference group (n-52) according to the random numerical table. The treatment of atovastatin was given to patients in the reference group, and the treatment group used athorvastatin therapy with dansanchuan injection, comparing the level changes of Hcy, h-CRP and CysC before and after treatment in the two groups, and comparing the clinical efficacy and the incidence of adverse reactions in the two groups. Results: After treatment, the above-mentioned indicators were significantly lower than before treatment (P 0.05), and the treatment group was significantly lower than the reference group (P 0.05), the clinical efficiency of the treatment group (86.54%) was significantly higher than that of the reference group (69.23%) (P 0.05), and the difference in the incidence of adverse reactions in the two groups was not significant (P.05). Conclusion: Dansanchuan injection in combination with atoflavatin therapy ACI, can significantly improve the patient's microcirculation, reduce Hcy, hs-CRP, CysC level, improve clinical efficacy.

[Abstract] Objective: To observe the effect of Salvia miltiorrhiza and ligustrazine injection combined with atorvastatin on homocysteine (Hcy), hypersensitive C-reactive protein (hs CRP) and cystatin C (CysC) in patients with acute cerebral infarction (ACI). Methods: 104 patients with ACI admitted from February 2018 to August 2019 were divided into treatment group (n = 52) and reference group (n = 52). The patients in the treatment group were treated with atorvastatin, while the patients in the treatment group were treated with Danshen and ligustrazine injection. The changes of Hcy, h-CRP and CysC levels before and after treatment were compared between the two groups, and the clinical efficacy and the incidence of adverse reactions were compared. Results: after treatment, the above indexes in the two groups were significantly lower than those before treatment (P < 0.05), and the clinical effective rate in the treatment group (86.54%) was significantly higher than that in the reference group (69.23%) (P < 0.05), and the incidence of adverse reactions in the two groups was not significantly different (P > 0.05). Conclusion: Salvia miltiorrhiza and ligustrazine injection combined with atorvastatin in the treatment of ACI can significantly improve microcirculation, reduce Hcy, hs CRP and CysC levels, and improve the clinical efficacy.